与ATP1A3基因变异相关的多巴响应性 dystonia 和阳性 dystonic 攻击
Míriam Carvalho Soares1,2, Jacy Bezerra Parmera2, Marcos Eugênio Ramalho Bezerra3
1Department of Neurology, Hospital das Clínicas, Federal University of Pernambuco, Recife, Brazil miriamcarvalhosoares@icloud.com.
Practical neurology
|March 7, 2024
概括
一名年轻男子患有早期发病的 dystonia,最初被误诊,在服用低剂量的乐伏多巴后显著改善. 这一案例强调了勒沃多巴试验对于复杂的 dystonia 呈现的价值.
科学领域:
- 神经学 神经学
- 遗传学 遗传学 是一个
- 运动障碍 运动障碍
背景情况:
- 早期发作的 dystonia 呈现出诊断上的挑战,经常模仿其他运动障碍.
- ATP1A3基因中的遗传变异与一系列神经疾病有关,包括非典型的 dystonia.
研究的目的:
- 报告一个早期发病的泛性 dystonia 病例,对levodopa 有积极反应.
- 突出整个外因组测序的诊断实用性和ATP1A3相关疾病中异常治疗反应的可能性.
主要方法:
- 一个18岁的男性从婴儿期就患有渐进性 dystonia 的临床病例介绍.
- 诊断工作包括神经学检查,实验室测试,脑磁共振成像和全外体测序.
- 用不同剂量的levodopa进行治疗试验.
主要成果:
- 最初被诊断为患有神经发作性中国性动力障碍症的患者在标准治疗中没有改善.
- 全外因子测序揭示了ATP1A3基因中的一种致病变体.
- 低剂量利沃多巴治疗 (25毫克每天两次) 显著改善了运动症状和生活质量,尽管初始的利沃多巴诱导的动力障碍在较高的剂量.
结论:
- 这一案例表明,在与ATP1A3相关的疾病中,对levodopa产生了罕见但显著的反应.
- 它强调了在复杂的早期发作的 dystonia 中考虑乐伏多巴试验的重要性,即使有非典型的遗传发现.
- 准确的基因诊断,例如识别ATP1A3变异,对于理解和管理这些罕见的神经疾病至关重要.
相关概念视频
Parkinson's Disease: Treatment
268
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
268
Parkinson's Disease: Overview
544
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
544
Drugs Affecting Neurotransmitter Synthesis
1.4K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.4K
Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin
680
Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...
The binding of dantrolene to the RYR1...
680
ATP Synthase: Mechanism
14.6K
In animals, the mitochondrial F1F0 ATP synthase is the key protein that synthesizes ATP molecules through a complex catalytic mechanism. While the nuclear genome encodes the majority of ATP synthase subunits, the mitochondrial genome encodes some of the enzyme's most critical components. The formation of this multi-subunit enzyme is a complex multi-step process regulated at the level of transcription, translation, and assembly. Defects in one or more of these steps can result in decreased...
14.6K
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
315
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
315


